PE targets immunotherapy: Five deals

Bain Capital, 65 Equity Partners, Arlington Capital Partners and Revelstoke Capital Partners are among the PE firms investing in the immunotherapy sector.

ByJohn R Fischer

15 August 2025•4 mins read

[data-article-body-skeleton]{display:none!important}

JavaScript is required to read this article. Please enable it in your browser and reload the page.

Featured Europe North America UK US Western Europe Healthcare Top Stories

PE targets immunotherapy: Five deals

65 Equity Partners

Arlington Capital Partners

Bain Capital

Gyrus Capital

Revelstoke Capital Partners